In summary, by utilizing bladder tumors as our disease model and employing GM‐CSF‐peptide and PD‐L1 nb as the therapeutic outputs, the bezafibrate‐regulated genetic switch demonstrates remarkable adaptability for controlling the in situ production of diverse therapeutic proteins aimed at cancer treatment. The gene discussed is CSF2; the disease is urinary bladder neoplasm.